Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 13, 2026
Reporting Period: Event date July 13, 2026
Business Context: The Company entered into a warrant inducement agreement to facilitate the exercise of existing Series C warrants and issued new warrants to the holder.
Key Financial Metrics and Transaction Details
- Expected Proceeds: Approximately $2.6 million in aggregate gross proceeds from the exercise of Existing Warrants (before fees and expenses).
- Shares Involved: 428,731 shares of common stock to be purchased via exercise of Existing Warrants.
- Exercise Price Adjustment: Existing Warrants exercise price reduced to $6.00 per share.
- New Securities Issued:
- Series D-1 Warrant: 428,731 shares, exercise price $5.75/share.
- Series D-2 Warrant: 428,731 shares, exercise price $5.75/share.
- Transaction Fees: 7.0% cash fee to Maxim Group LLC (warrant solicitation agent) plus expense reimbursement up to $15,000.
- Warrant Term: 5.5 years from issuance for New Warrants.
Material Changes Versus Prior Period
This filing reports a discrete corporate event rather than a periodic financial performance update. Consequently, there are no comparative revenue, profit, or cash flow metrics provided for this period versus a prior period. The material change is the restructuring of the capital structure through the reduction of the exercise price on Series C warrants and the issuance of new Series D-1 and D-2 warrants.
Guidance, Outlook, and Risks
- Management Commentary: The Company anticipates receiving gross proceeds of approximately $2.6 million. No specific operational guidance or future revenue outlook is provided in this filing.
- Registration Status: The Company agreed to file a resale registration statement for the New Warrant Shares within 15 calendar days and use commercially reasonable efforts to have it declared effective within 45 days (or 75 days if reviewed by the SEC).
- Beneficial Ownership Limitation: The Holder may not exercise warrants if it results in beneficial ownership exceeding 4.99% or 9.99% (at Holder's election) of outstanding shares.
- Fundamental Transaction Rights:
- Series D-1: Holder has a right to receive Black Scholes value in cash if the transaction is within Company control.
- Series D-2: Holder receives consideration similar to common stock holders but lacks Black Scholes redemption rights.
- Risk Disclosure: Representations and warranties in the Inducement Letter are for risk allocation between parties and not statements of fact for investors; information may change after the date of the letter.
Investor Verification Checklist
- Verify the actual cash proceeds received after deducting the 7.0% advisory fee and offering expenses.
- Confirm the effective date of the Resale Registration Statement for the New Warrant Shares.
- Monitor the Company's cash balance to assess the impact of the $2.6 million inflow on liquidity.
- Review the dilution impact of the 428,731 shares from the Existing Warrants and the potential future issuance of up to 857,462 shares from the New Warrants.
- Check for any subsequent filings regarding the status of the Series D-1 and D-2 warrants.